Results
|
|
1.
|
Baseline Characteristics of the VANISH Cohort. MedStar authors:
Year: 2019
Citation: - Circulation: Heart Failure. 12(12):e006231, 2019 12.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Axelsson Raja A, Bach R, Becker J, Benson L, Braunwald E, Bundgaard H, Canter C, Choudhury L, Cirino AL, Colan SD, Day SM, Hall EK, Ho CY, Jefferies JL, Lever H, Lewis GD, Lin KY, MacRae CA, Margossian R, McMurray JJV, Mestroni L, Murphy AM, Orav EJ, Owens AT, Pahl E, Patel AR, Pereira AC, Rossano J, Russell M, Shi L, Solomon SD, Taylor M, Vargas JD, Wheeler MT, Zahka K
|
|
|
2.
|
Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. MedStar authors:
Year: 2019
Citation: - Diabetes Care. 42(12):2262-2271, 2019 12.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Araki E, Aroda VR, Buse JB, Cariou B, Harris SB, Hoff ST, Pedersen KB, PIONEER 8 investigators, Tarp-Johansen MJ, Zinman B
|
|
|
3.
|
Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study).[Erratum appears in Diabetes Obes Metab. 2016 Sep;18(9):952; PMID: 27546838] MedStar authors:
Year: 2016
Citation: - Diabetes, Obesity & Metabolism. 18(7):663-70, 2016 Jul
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Andersen TH, Aroda VR, Bailey TS, Cariou B, Kumar S, Leiter LA, Philis-Tsimikas A, Raskin P, Zacho J
|
|
|
4.
|
Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial. MedStar authors:
- Miodovnik, Menachem
- Umans, Jason G
Year: 2015
Citation: - BMC Pregnancy & Childbirth. 15:59, 2015.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Caritis SN, Clark S, Hankins GD, Koren G, Matok I, Mattison DR, Miodovnik M, Umans JG
|
|
|
5.
|
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. MedStar authors:
Year: 2015
Citation: - Lancet. 386(9992):452-60, 2015 Aug 1.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Barter PJ, Brewer HB, Ford J, Hovingh GK, Kastelein JJ, Rader DJ, Round P, Saleheen D, van Deventer SJ
|
|
|
6.
|
AST-120 (spherical carbon adsorbent) in the treatment of perianal fistulae in mild-to-moderate Crohn's disease: FHAST-1, a phase 3, multicenter, placebo-controlled study. MedStar authors:
- Shara, Nawar M
- Wang, Hong
Year: 2014
Citation: - Inflammatory Bowel Diseases. 20(5):872-81, 2014 May.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Hanauer S, Harris MS, Reinisch W, Shara N, Travis S, Wang H
|
|
|
7.
|
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). MedStar authors:
Year: 2014
Citation: - Journal of Diabetes & its Complications. 28(3):386-92, 2014 May-Jun.
Institution: - MedStar Health Research Institute
Medline publication type:
- Clinical Trial, Phase III
- Journal Article
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - Boka G, Hanefeld M, Min KW, Miossec P, Muehlen-Bartmer I, Ratner RE, Rosenstock J, Shamanna P, Zhou T
|
|
|
8.
|
|
|
|
9.
|
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. MedStar authors:
Year: 2013
Citation: - Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D
|
|
|
10.
|
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History). MedStar authors:
Year: 2012
Citation: - The International Journal of Cardiovascular Imaging. 28(3):455-65, 2012 Mar.
Institution: - MedStar Health Research Institute
Medline publication type:
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
All authors: - APPROACH study group, Brugaletta S, Garcia-Garcia HM, Garg S, Huang C, Kolatkar NS, Kravitz BG, Miller DM, Morocutti G, Nesto RW, Ratner RE, Serruys PW
|
